Share on StockTwits
 

CME Group (NYSE:CME) was upgraded by equities research analysts at TheStreet from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, AnalystRatings.Net reports.

The analysts wrote, “CME Group (CME) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”

CME Group (NYSE:CME) traded up 0.02% during mid-day trading on Wednesday, hitting $76.565. 183,924 shares of the company’s stock traded hands. CME Group has a 1-year low of $56.60 and a 1-year high of $84.71. The stock has a 50-day moving average of $76.03 and a 200-day moving average of $75.91. The company has a market cap of $25.545 billion and a P/E ratio of 26.22.

CME Group (NYSE:CME) last announced its earnings results on Tuesday, February 4th. The company reported $0.64 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.68 by $0.04. The company had revenue of $687.00 million for the quarter, compared to the consensus estimate of $691.29 million. During the same quarter last year, the company posted $0.63 earnings per share. CME Group’s revenue was up 3.9% compared to the same quarter last year. On average, analysts predict that CME Group will post $3.58 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, March 25th. Stockholders of record on Monday, March 10th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.46%. The ex-dividend date is Thursday, March 6th. This is a boost from CME Group’s previous quarterly dividend of $0.45.

In other CME Group news, Director C Odom II sold 2,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $73.59, for a total transaction of $147,180.00. Following the transaction, the director now directly owns 6,003 shares in the company, valued at approximately $441,761. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of other analysts have also recently weighed in on CME. Analysts at Zacks reiterated a “neutral” rating on shares of CME Group in a research note on Wednesday, February 5th. They now have a $77.00 price target on the stock. Separately, analysts at BMO Capital Markets cut their EPS estimates on shares of CME Group in a research note on Wednesday. They now have an “outperform” rating and a $85.00 price target on the stock. Finally, analysts at Citigroup Inc. downgraded shares of CME Group from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 8th. They now have a $82.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $72.31.

CME Group Inc (NYSE:CME) offers a range of global products across all asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.